Pete Rahl is the founder of Kronos Bio. He is involved in exploring the utility of p300 KAT inhibitors for autoimmune indications.
Peter Rahl, Ph.D., serves as the Vice President of Discovery Biology at Kronos Bio, a company focused on developing small molecule therapeutics for cancers and other diseases linked to deregulated transcription. He is involved in exploring the utility of p300 KAT inhibitors for autoimmune indications, leveraging the company's discovery engine to modulate pro-inflammatory signaling pathways.
Full founder directory · Investor directory · Company funding database · Fundraising library